BCG (Tokyo 172) vaccine
2019-01
Phase 3 mab terminated
Quick answer
BCG (Tokyo 172) vaccine for Tuberculosis Infection is a Phase 3 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Tuberculosis Infection
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated